You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四环医药(00460.HK)利拉鲁(月太)完成减肥适应症一期临床研究
阿思达克 02-26 12:12
四环医药(00460.HK)公布,旗下利拉鲁(月太)(liraglutide)项目开发适应症为2型糖尿病和肥胖的治疗,目前已完成第一期临床研究,并初步获得了药代动力学和药效学的生物等效性结果,正就肥胖症三期开发计划沟通中,预期不久将进入临床三期阶段。

利拉鲁(月太)为胰高血糖素样(月太)-1(GLP-1)激动剂,已被美国食品药品管理局批准用於治疗成人及十岁以上的2型糖尿病患者,用於降低患者心脏病发作、卒中及心血管死亡风险,集团的利拉鲁(月太)产品目前预计将专注於中国市场。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account